Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06581406 · ClinicalTrials.gov registry record · Phase 2
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
A Phase 2 study of Metastatic Uveal Melanoma, sponsored by Replimune.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 280
- Enrollment target
- 20
- Study locations
NCT06581406: Recruiting Phase 2 study of Metastatic Uveal Melanoma, sponsored by Replimune.
NCT06581406 is a Phase 2 study of Metastatic Uveal Melanoma that is actively recruiting participants, run by Replimune. The registered enrollment target is 280 participants, above the 113-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (148% higher). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06581406, a Phase 2 study of Metastatic Uveal Melanoma, is actively recruiting participants, sponsored by Replimune.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 280 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Primary Outcome
OS is the time from the date of randomization to death from any cause.
Conditions Studied
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL Ipilimumab
- BIOLOGICAL RP2
Study Locations (20)
California
- UC San Diego Moores Cancer Center - La Jolla
- The Angeles Clinic and Research Institute - Los Angeles
- University of California Los Angeles - Los Angeles
- Stanford Cancer Institute - Palo Alto
Colorado
- University of Colorado Hospital - Anschutz Cancer Pavilion(ACP) - Aurora
- The Melanoma & Skin Cancer Institute - Englewood
Florida
- Mayo Clinic - Jacksonville FL - Jacksonville
- Sylvester Comprehensive Cancer Center - Miami
Illinois
- Northwestern Memorial Hospital - Chicago
- University of Chicago Medical Center - Chicago
Arizona
- HonorHealth Research Insisute - Scottsdale
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Georgia
- Emory Winship Cancer Institute - Atlanta
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 280 participants |
| Start Date | 2024-12-17 |
| Est. Completion | 2031-10 |
| Phase | Phase 2 |
What NCT06581406 shows while recruiting
NCT06581406 is an interventional study that assigns participants to a tested intervention. The registered 280 participants enrollment target is mid-sized for trials with a published cap, above the 113-participant average among 14 other Metastatic Uveal Melanoma trials with a reported enrollment target (148% higher).
The record links to 1 condition, with Metastatic Uveal Melanoma appearing as the primary indexed condition, and to 3 interventions - of which Nivolumab is the first listed.
NCT06581406 names 20 study sites across 14 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT06581406 about?
NCT06581406 is a clinical study titled "A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma". The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
What is the current status of trial NCT06581406?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 280 participants. The study started on 2024-12-17. Estimated completion is 2031-10.
What conditions does trial NCT06581406 study?
This clinical trial studies the following conditions: Metastatic Uveal Melanoma.
What interventions are being tested in trial NCT06581406?
The interventions under investigation include: Nivolumab (BIOLOGICAL), Ipilimumab (BIOLOGICAL), RP2 (BIOLOGICAL).
Who is sponsoring clinical trial NCT06581406?
This trial is sponsored by Replimune, which has 9 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06581406 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06581406's enrollment target sits among peer trials
280 4th of 14 higher than 11 of 14 other Metastatic Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study of Tebentafusp and Radioembolization in the Treatment of Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases
ACTIVE NOT RECRUITING · Phase 2
-
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
-
IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal Melanoma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04084730 · 280 participants · Phase 2
Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
- NCT04518657 · 280 participants · NA
Internet-Delivered Lifestyle Physical Activity Intervention for Cognitive Processing Speed in Multiple Sclerosis
- NCT04634916 · 280 participants · NA
Post-market Surveillance Study of the BD® WavelinQ™ EndoAVF System
- NCT04829617 · 280 participants · NA
Promoting Well-being and Health in Heart Failure
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI